Johnson & Johnson Push Ahead With Invega Franchise
This article was originally published in The Pink Sheet Daily
Firm files response to “complete response” letter for once-monthly version and tries for new indication for once-daily paliperidone.
You may also be interested in...
Ustekinumab “complete response” letter requests medication guide and communication plan, but not restricted distribution.
New dosing option for the atypical antipsychotic will be included in the NDA resubmission.
Could management’s lack of enthusiasm for the schizophrenia drug foreshadow a delay at FDA?